Nkarta announces proposed public offering of common stock

South san francisco, calif., april 25, 2022 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced that it has commenced a proposed underwritten public offering to issue and sell $150 million of shares of its common stock. the company also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock on the same terms and conditions. the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. all shares in the offering are to be issued and sold by nkarta.
NKTX Ratings Summary
NKTX Quant Ranking